A detailed history of First Trust Advisors LP transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 28,351 shares of TGTX stock, worth $837,488. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,351
Previous 156,828 81.92%
Holding current value
$837,488
Previous $2.79 Million 76.23%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$17.21 - $25.28 $2.21 Million - $3.25 Million
-128,477 Reduced 81.92%
28,351 $663,000
Q2 2024

Aug 13, 2024

SELL
$13.32 - $19.19 $156,296 - $225,175
-11,734 Reduced 6.96%
156,828 $2.79 Million
Q1 2024

May 13, 2024

BUY
$13.02 - $21.3 $1.69 Million - $2.77 Million
129,995 Added 337.06%
168,562 $2.56 Million
Q4 2023

Feb 13, 2024

SELL
$6.68 - $18.81 $689,462 - $1.94 Million
-103,213 Reduced 72.8%
38,567 $658,000
Q3 2023

Nov 13, 2023

SELL
$8.36 - $26.5 $141,852 - $449,652
-16,968 Reduced 10.69%
141,780 $1.19 Million
Q2 2023

Aug 14, 2023

BUY
$15.48 - $35.0 $2.46 Million - $5.56 Million
158,748 New
158,748 $3.94 Million
Q4 2021

Feb 08, 2022

SELL
$15.2 - $35.51 $330,144 - $771,277
-21,720 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$21.78 - $40.45 $487,959 - $906,241
-22,404 Reduced 50.78%
21,720 $723,000
Q2 2021

Aug 16, 2021

SELL
$32.5 - $48.96 $1.16 Million - $1.75 Million
-35,656 Reduced 44.69%
44,124 $1.71 Million
Q1 2021

May 14, 2021

BUY
$41.61 - $54.3 $244,916 - $319,609
5,886 Added 7.97%
79,780 $3.85 Million
Q4 2020

Feb 02, 2021

SELL
$25.27 - $54.9 $196,499 - $426,902
-7,776 Reduced 9.52%
73,894 $3.84 Million
Q3 2020

Nov 05, 2020

SELL
$18.49 - $27.24 $490,724 - $722,949
-26,540 Reduced 24.53%
81,670 $2.19 Million
Q2 2020

Jul 22, 2020

BUY
$8.9 - $21.84 $963,069 - $2.36 Million
108,210 New
108,210 $2.11 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.